DRUG INTERACTIONS

Drug-drug interaction trials of remdesivir and other concomitant medications have not been conducted in humans. In vitro, remdesivir is a substrate for drug metabolizing enzymes CYP2C8, CYP2D6, and CYP3A4, and is a substrate for organic anion transporting polypeptides 1B1 (OAPT1B1) and P-glycoprotein (Pgp) transporters. In vitro, remdesivir is an inhibitor of CYP3A4, OATP1B1, OATP1B3, BSEP, MRP4, and NTCP. The clinical relevance of these in vitro assessments has not been established.

DESREM™, Remdesivir Prescribing Information. Mylan Laboratories Limited. 2020.

India Health Care Professional

Health Care Professional Outside India

This website is for Healthcare Professionals only.

Please confirm if you are a healthcare professional.

Yes, I am

Disclaimer: Mylan, a Viatris company does not recommend the use of its product Desrem^™ (Remdesivir for injection 100mg/vial, hereinafter, the “Product”) in any manner inconsistent with that described in the full prescribing information. The data contained in this microsite is for medical and scientific informational purposes only. Information presented on the microsite should not be construed as advice or recommendation for using the Product. Mylan, a Viatris company expressly disclaims liability for any undue consequences arising out of off-label use of the Product. Mylan, a Viatris company or any of its affiliates, directors, employees, officers, consultants, service providers shall not be responsible in any manner whatsoever, for any action taken, opinions expressed, advice rendered or accepted, any direct, incidental, special or consequential loss and damage caused on the basis of any material or information presented on this microsite. Please refer to full prescribing information before prescribing the Product.